Published in Obesity and Diabetes Week, April 18th, 2005
The combined company will have annual revenue in excess of $700 million, operations in more than 12 countries, businesses in over 60 countries, and approximately 1,500 employees.
The combined entity will have a portfolio of complementary products in the facial asthetics, breast asthetics and therapeutic dermatological markets, and innovative surgical devices for the treatment of morbid obesity.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week